GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Institutional Ownership

Noile-Immune Biotech (TSE:4893) Institutional Ownership : 0.92% (As of Jun. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Noile-Immune Biotech's institutional ownership is 0.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Noile-Immune Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Noile-Immune Biotech's Float Percentage Of Total Shares Outstanding is 0.00%.


Noile-Immune Biotech Institutional Ownership Historical Data

The historical data trend for Noile-Immune Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Institutional Ownership Chart

Noile-Immune Biotech Historical Data

The historical data trend for Noile-Immune Biotech can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30
Institutional Ownership 1.23 0.93 0.92 0.92 0.92 0.92

Noile-Immune Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines